
Protagenic Therapeutics, Inc.\new
OTC · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Protagenic Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based therapeutics derived from neuropeptide research, with its lead candidate PT00114 being studied for stress and anxiety-related disorders.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF | Buy | $10K | 16,634at $0.59 | Aug 20, 2026 |
| ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF | Buy | $945 | 2,700at $0.35 | Aug 19, 2026 |
| ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF | Buy | $151 | 685at $0.22 | Aug 6, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PTIX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.